Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNP | P00491 | 4/20 | 1.00 |
| ▸ | LMNA | P02545 | 4/20 | 0.76 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.76 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.76 |
| ▸ | TSHR | P16473 | 2/20 | 0.76 |
| ▸ | THPO | P40225 | 2/20 | 0.76 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.76 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.76 |
| ▸ | GLA | P06280 | 1/20 | 0.76 |
| ▸ | EIF4E | P06730 | 1/20 | 0.76 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.76 |
| ▸ | TOP1 | P11387 | 1/20 | 0.76 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | HTT | P42858 | 2/20 | 0.47 |
| ▸ | BLM | P54132 | 2/20 | 0.47 |
| ▸ | TP53 | P04637 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | GMNN | O75496 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Taribavirin SCHEMBL3868643 | 1.00 | PNP (1.00) | PNPLMNASMN1; SMN2ALDH1A1TSHR | |
| Taribavirin SCHEMBL2619250 | 1.00 | PNP (1.00) | PNPLMNASMN1; SMN2ALDH1A1TSHR | |
| Taribavirin SCHEMBL12758161 | 1.00 | PNP (1.00) | PNPLMNASMN1; SMN2ALDH1A1TSHR | |
| Taribavirin SCHEMBL3307695 | 1.00 | PNP (1.00) | PNPLMNASMN1; SMN2ALDH1A1TSHR | |
| Taribavirin SCHEMBL4967368 | 1.00 | PNP (1.00) | PNPLMNASMN1; SMN2ALDH1A1TSHR | |
| Taribavirin SCHEMBL16330745 | 1.00 | PNP (1.00) | PNPLMNASMN1; SMN2ALDH1A1TSHR | |
| Taribavirin SCHEMBL6981526 | 1.00 | PNP (1.00) | PNPLMNASMN1; SMN2ALDH1A1TSHR | |
| Taribavirin SCHEMBL2631656 | 1.00 | PNP (1.00) | PNPLMNASMN1; SMN2ALDH1A1TSHR | |
| Taribavirin SCHEMBL18735565 | 1.00 | PNP (1.00) | PNPLMNASMN1; SMN2ALDH1A1TSHR | |
| Taribavirin SCHEMBL40670 | 1.00 | PNP (1.00) | PNPLMNASMN1; SMN2ALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10472677-B2 | Translational dysfunction based therapeutics | TRANSLATIONAL THERAPEUTICS, INC. (US) | 2019-11-12 | — | — | US | disclosed |
| US-20180207145-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING DANIRIXIN FOR TREATING INFECTIOUS DISEASES | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED | 2018-07-26 | — | — | US | disclosed |
| US-20170100385-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING DANIRIXIN FOR TREATING INFECTIOUS DISEASES | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) | 2017-04-13 | — | — | US | disclosed |
| US-20150290235-A1 | USE OF SMALL MOLECULE INHIBITORS/ACTIVATORS IN COMBINATION WITH (DEOXY)NUCLEOSIDE OR (DEOXY)NUCLEOTIDE ANALOGS FOR TREATMENT OF CANCER AND HEMATOLOGICAL MALIGNANCIES OR VIRAL INFECTIONS | AB SCIENCE (FR) | 2015-10-15 | — | — | US | disclosed |
| US-8497292-B2 | Translational dysfunction based therapeutics | TRANSLATIONAL THERAPEUTICS, INC. (US) | 2013-07-30 | — | — | US | disclosed |
| US-20130109730-A1 | TREATMENT OF LIVER DISEASES IN WHICH IRON PLAYS A ROLE IN PATHOGENESIS | NOVARTIS AG (CH) | 2013-05-02 | — | — | US | disclosed |
| US-20100098662-A1 | TREATMENT OF LIVER DISEASES IN WHICH IRON PLAYS A ROLE IN PATHOGENESIS | ALBERTI DANIELE M | 2010-04-22 | — | — | US | disclosed |
| US-20090163564-A1 | Translational Dysfunction Based Therapeutics | TRANSLATIONAL THERAPEUTICS, INC. (US) | 2009-06-25 | — | — | US | disclosed |
| US-20080199428-A1 | Treatment of Liver Diseases in Which Iron Plays a Role in Pathogenesis | ALBERTI DANIELE M | 2008-08-21 | — | — | US | disclosed |
| EP-1893198-A2 | TREATMENT OF LIVER DISEASES IN WHICH IRON PLAYS A ROLE IN PATHOGENESIS | Novartis AG (CH) | 2008-03-05 | — | — | EP | disclosed |
| WO-2006130532-A2 | TREATMENT OF LIVER DISEASES IN WHICH IRON PLAYS A ROLE IN PATHOGENESIS | NOVARTIS AG (CH) | 2006-12-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180207145-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING DANIRIXIN FOR TREATING INFECTIOUS DISEASES | DDOST, DHX30, DDX5 | PNP 741/4885LMNA 2832/4885SMN1; SMN2 130/4885 |
| US-20130109730-A1 | TREATMENT OF LIVER DISEASES IN WHICH IRON PLAYS A ROLE IN PATHOGENESIS | TFRC, FABP1, HAMP | PNP 2405/4885LMNA 2519/4885SMN1; SMN2 4344/4885 |
| US-10472677-B2 | Translational dysfunction based therapeutics | EIF4EBP1, EIF4E, EIF4A1 | PNP 1035/4885LMNA 3062/4885SMN1; SMN2 699/4885 |
| US-20100098662-A1 | TREATMENT OF LIVER DISEASES IN WHICH IRON PLAYS A ROLE IN PATHOGENESIS | TFRC, FABP1, HAMP | PNP 2405/4885LMNA 2519/4885SMN1; SMN2 4344/4885 |
| US-20090163564-A1 | Translational Dysfunction Based Therapeutics | EIF4EBP1, EIF4E, EIF4A1 | PNP 1035/4885LMNA 3062/4885SMN1; SMN2 699/4885 |
| US-20150290235-A1 | USE OF SMALL MOLECULE INHIBITORS/ACTIVATORS IN COMBINATION WITH (DEOXY)NUCLEOSIDE OR (DEOXY)NUCLEOTIDE ANALOGS FOR TREATMENT OF CANCER AND HEMATOLOGICAL MALIGNANCIES OR VIRAL INFECTIONS | DCK, ADK, DTYMK | PNP 16/4885LMNA 2728/4885SMN1; SMN2 3166/4885 |
| US-20170100385-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING DANIRIXIN FOR TREATING INFECTIOUS DISEASES | DDOST, DHX30, DDX5 | PNP 741/4885LMNA 2832/4885SMN1; SMN2 130/4885 |
| US-20080199428-A1 | Treatment of Liver Diseases in Which Iron Plays a Role in Pathogenesis | TFRC, FABP1, HAMP | PNP 2405/4885LMNA 2519/4885SMN1; SMN2 4344/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.